A Cornell-led collaboration devised a potentially low-cost method for producing antibodies for therapeutic treatments: bioengineered bacteria with an overlooked enzyme that can help monoclonal antibodies boost their immune defenses.
Read the story in the Cornell Chronicle.
Doctoral students engage in advocacy
Cornell University Graduate School
